亚特美可以通过调节骨肌肉中的糖脂代谢来改善1型糖尿病
Yifan Dong1, Qike Fu2, Yating Zhang1
1Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine Shenzhen 518033, Guangdong, China.
American journal of translational research
|September 15, 2025
概括
一种抗疟疾药物阿尔特美在治疗1型糖尿病 (T1D) 中表现有前途. 它有效地改善了骨肌肉中的葡萄糖和脂质代谢,减轻了小鼠的糖尿病症状.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病的特点是葡萄糖和脂质平衡被破坏.
- 骨肌肉在胰岛素敏感性和代谢调节中起着关键作用.
- 准骨肌肉代谢是一种潜在的糖尿病治疗策略.
研究的目的:
- 为了研究甲基的抗糖尿病和降脂作用.
- 为了阐明甲基调节1型糖尿病骨肌肉代谢的机制.
主要方法:
- 一种1型糖尿病小鼠模型被诱导使用链条毒素.
- 小鼠接受了8周的阿美治疗,评估了血糖,HbA1c和骨肌肉代谢.
- 分析包括生物化学分析,组织学染色,免疫光,免疫阻塞和qPCR.
主要成果:
- 在1型糖尿病小鼠中,甲基治疗显著降低了禁食血糖和HbA1c水平.
- 在骨肌肉中,甲胺抑制了pyruvate dehydrogenase kinase 4并激活了pyruvate dehydrogenase.
- 这导致了增强的有氧葡萄糖代谢和抑制脂肪酸代谢.
结论:
- 在1型糖尿病小鼠模型中,Artemether表现出显著的抗糖尿病作用.
- 该药物通过调节骨肌肉中的糖脂代谢来缓解糖尿病症状.
- 亚特美代表了通过代谢干预来管理糖尿病的潜在治疗剂.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K

